OmniAb to Hold OmniUltra Virtual Investor Event on December 15

Key Terms

virtual investor event financial

A virtual investor event is an online gathering where companies share updates about their business, financial performance, or strategic plans with current or potential investors. It functions like a detailed presentation or meeting conducted over the internet, allowing investors to learn more about a company without attending in person. These events help investors stay informed and make decisions based on the latest company insights.

OmniUltra technical

Omniultra is a term used to describe a highly advanced and comprehensive technology or system that integrates multiple functions or capabilities into one unified platform. For investors, it signifies a tool or solution that offers broad, all-in-one access to information or services, making decision-making more efficient and informed. Think of it as a smartphone that combines calling, navigation, photography, and internet access into a single device—streamlining multiple needs into one seamless experience.

transgenic chicken medical

A transgenic chicken is a chicken that has had its genetic material altered by adding new genes from another organism. This modification can improve traits like growth speed, disease resistance, or nutritional content. For investors, such biotechnology advancements can create opportunities in agriculture, food production, and related industries by enabling the development of improved or novel products.

ultralong CDRH3 domains medical

Ultralong CDRH3 domains are specialized regions within an antibody that extend far out from its main structure, allowing it to reach and recognize unusual or hidden targets. For investors, understanding these domains is important because they enable the development of highly precise therapies and diagnostics, potentially leading to significant advances in medicine and new commercial opportunities. Their unique structure can influence the effectiveness and innovation potential of biotech products.

human antibody framework medical

A human antibody framework is the core structure of an antibody molecule that provides stability and shape, allowing it to effectively recognize and latch onto specific targets, such as viruses or bacteria. For investors, understanding this framework is important because it influences how well antibody-based medicines work and their potential success in the market, impacting the development and approval of new therapies.

webcast technical

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

Conference ID technical

A conference ID is a unique code used to identify and join a specific online meeting or conference call. It functions like a digital key, ensuring that only authorized participants can access the session. For investors, a conference ID helps them connect securely to important discussions or announcements, providing timely access to information that can impact markets or investment decisions.

EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra^™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time.

The event is expected to last approximately one hour and will include a review of OmniAb’s newest technology offering, OmniUltra, the industry's only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. Management will provide an overview of this innovative and pioneering technology platform, its market use and applications, as well as its strategic importance to the business.

Conference Call and Webcast Information

What:		OmniUltra Launch Virtual Investor Event
Date:		Monday, December 15, 2025
Time:		5:00 p.m. Eastern time (2:00 p.m. Pacific time)
Phone:		U.S. (800) 549-8228
		International (646) 564-2877
		Conference ID is 44666
Webcast:		Live and replay webcast of the call with slides will be available here.

About OmniAb^®

OmniAb licenses cutting edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, is used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.

For more information, please visit www.omniab.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251204562934/en/

OmniAb, Inc.

investors@OmniAb.com

X @OmniAbTech



Alliance Advisors IR

Yvonne Briggs

ybriggs@allianceadvisors.com

(310) 691-7100

Source: OmniAb, Inc.